Navigation Links
Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program
Date:7/21/2014

BEIJING, July 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Health Bureau as the sole supplier of inactivated hepatitis A vaccine in pre-filled syringe dosage to the Expanded Program of Immunization (EPI) for Beijing. The tender is valued at approximately 16 million RMB. The vaccines purchased by the Beijing Health Bureau will be used for the period from 2014 to 2016. The Company expects to begin delivery in the coming months upon the demand.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are pleased to have been selected again as the only supplier of the inactivated hepatitis A vaccine in PFS presentation to the EPI in Beijing. With superior safety profile and proven efficacy, Healive will continue to be administered to newborns using our easy-to-use, pre-filled syringes. We look forward to continuing to collaborate with government agencies to control and prevent diseases with top-quality vaccines both in China and around the world."

Healive is the first inactivated hepatitis A vaccine developed, produced and marketed by a China-based manufacturer. Healive was launched by Sinovac in 2002 and is currently available in adult and pediatric dosages. The hepatitis A vaccine has been included in China's national immunization program since February 2008.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. The Company filed a new drug application for enterovirus 71 (against hand, foot and mouth disease) with China Food & Drug Administration. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella, and sIPV. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize seasonal flu vaccine in Mexico and hepatitis A vaccine in Chile.   

Contact

Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com

ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com

 

 


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
2. Sinovac Reports Unaudited First Quarter 2012 Financial Results
3. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
4. Sinovac Schedules 2012 Annual Meeting of Shareholders
5. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
7. Sinovac Holds 2012 Annual General Meeting of Shareholders
8. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
9. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
10. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
11. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... May 25, 2016 Digital Health Dialog, ... it by the US Patent and Trademark Office ... includes proprietary processes for electronic opt-­in and processing ... wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for individuals ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... 2016 , ... There are nearly 14.5 million people living with and beyond ... Sunday, June 5, 2016, communities around the world will gather to recognize these cancer ... Cancer Survivors Day® is an annual worldwide Celebration of Life that is held on ...
(Date:5/26/2016)... Los Angeles, CA (PRWEB) , ... May 26, 2016 , ... In an effort to ... Snapchat videos available to both Snapchat users and those who do not use the app. ... available on his new page, Dr. Mohebi Live . , Dr. Mohebi says, ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... North ... May 13 at Blackhorse Golf Club in Cypress. With the help of community partners, ... that restores, empowers, and renews hope for wounded service members and their families through ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a leading developer ... Instructor Certification Course in Stoughton, Massachusetts. The course was led by Power Systems’ ... 8 hour interactive course to qualify participants as certified PowerWave trainers. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our professional athletes coincides with ... ™”. , “We are proud to introduce Meghan Klingenberg, defender and World ... Brian Quick, wide receiver for Los Angeles who was a second round selection in ...
Breaking Medicine News(10 mins):